-
Featured
Verdiva Bio joins weight loss race with $411M Series A
January 9, 2025The London-based company’s launch coincides with a sharp increase of VC funding for weight loss companies.Article
Learn more » -
Private Equity
RFK Jr. nomination dents PE confidence in CRO market
December 12, 2024Vaccine scrutiny could raise clinical trial standards, which poses a risk to fund managers with significant investments in CROs.Article
Learn more » -
Healthcare
Pharma services dealmaking nears quarterly record
November 18, 2024PE deal activity in the sector is riding tailwinds from M&A-friendly interest rate policies and GPs’ growing appetite for life sciences investments.Article
Learn more » -
Biotech
Has PE fallen out of love with Europe’s biotech industry?
September 26, 2024Data from the last five years shows that investment in biotech is dropping sharply with no signs of recovery.Article
Learn more » -
Biopharma
Candid Therapeutics launches with $370M and a pair of acquisitions
September 9, 2024The startup focuses on repurposing cancer treatments for hard-to-treat autoimmune disorders.Article
Learn more » -
Top Investor
Biotech’s top 10 most active VC investors
September 4, 2024The nascent application of AI in biotech and drug discovery is helping fuel a surge in valuations of venture-backed biopharma startups.Article
Learn more » -
Biotech
Hot biotech stocks have LPs eyeing hybrid venture vehicles
July 16, 2024In an interview with PitchBook, Stephanie Sirota, RTW Ventures’ chief business officer, says that the veteran venture capitalist’s outlook on biotech has never been brighter—but it takes money to make money.Article
Learn more » -
Biotech
Foresite Capital’s $900M VC fund bets on AI to aid biotech plays
June 12, 2024Foresite’s latest fund follows a 2023 comeback for early-stage biopharma startups, with median pre-money valuations soaring 33% year-over-year.Article
Learn more » -
Healthcare
Why early-stage biopharma valuations have surged
February 23, 2024Biotech investors become choosier during market downturns, paying higher prices for fewer companies.Article
Learn more » -
VC Fundraising
Arch Venture Partners targets $3B Fund XIII in most ambitious raise to date
February 1, 2024Chicago-based Arch Venture Partners has set ambitious sights for 2024, sending a bullish signal for life sciences and biotech fundraising.Article
Learn more » -
IPO
Biotech IPO surge sparks hope for tech offerings
February 1, 2024The IPO calendar for biotech listings has filled up. Will tech companies follow suit?Article
Learn more » -
Top Investor
Meet the 5 most active PE investors in life sciences
December 3, 2023The life sciences industry has drawn considerable interest from private equity, which injects billions of dollars into this rapidly growing segment.Article
Learn more » -
Top Investor
KKR leads the way in PE biotech dealmaking
September 5, 2023KKR is the most active investor in the high-stakes biotech PE sector, where a winning product can be extremely lucrative.Article
Learn more » -
Biotech
Investors bet on generative AI to revolutionize drug discovery
August 23, 2023While there are still not many biotech startups that are employing generative AI methods to create novel drug compounds, some early adopters have succeeded in raising substantive funding in recent months.Article
Learn more » -
Biotech
VCs inject $3.2B into defense-focused biotechnology
May 29, 2023The pandemic supercharged investment in mission-critical biotechnology, making it one of the most well-funded areas of defense tech.Article
Learn more » -
VC Fundraising
Cure Ventures debuts with $350M life sciences fund
April 2, 2023Cure Ventures, a firm launched by biopharma veterans, has closed its inaugural $350 million fund for backing both novel drugs and medicines already undergoing clinical trials.Article
Learn more » -
Biotech
Sanofi to bolster its VC unit with $750M commitment
January 11, 2023Pharmaceutical company Sanofi has agreed to a multiyear commitment to invest over $750 million in its corporate venture capital arm.Article
Learn more » -
M&A
BioNTech to join push into AI drug discovery with InstaDeep deal
January 10, 2023Biotech company BioNTech is set to buy UK-based AI startup InstaDeep for up to £562 million.Article
Learn more »